essential for older adults. However, there are few data on functional outcomes after cancer surgery, with most studies limited to 6- to 12-month time horizons. 12 – 19 Lack of data regarding these outcomes impacts the accuracy of prognostication and can
Search Results
Association Between Frailty and Time Alive and At Home After Cancer Surgery Among Older Adults: A Population-Based Analysis
Julie Hallet, Bourke Tillman, Jesse Zuckerman, Matthew P. Guttman, Tyler Chesney, Alyson L. Mahar, Wing C. Chan, Natalie Coburn, Barbara Haas, and members of the Recovery after Surgical Therapy for Older adults Research–Cancer (RESTORE-Cancer) Group
Associations Between Surrogates’ Decisional Regret Trajectories and Bereavement Outcomes
Fur-Hsing Wen, Chia-Hsun Hsieh, Wen-Chi Shen, Ming-Mo Hou, Po-Jung Su, Wen-Chi Chou, Jen-Shi Chen, Wen-Cheng Chang, and Siew Tzuh Tang
, particularly for unfavorable outcomes, 19 and to avoid negative bereavement outcomes that can last several months or years. 15 , 16 Indeed, higher decisional regret is associated with worse bereavement outcomes, including increased symptoms of anxiety, 20
Point: Fluoroquinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Cancer Patients Works for Defined Outcomes in Defined Populations, but Must Be Used Wisely
Eric J. Bow
economic outcomes of hematopoietic stem-cell transplantation . J Clin Oncol 2001 ; 19 : 2201 – 2205 . 12 Sonis ST Elting LS Keefe D . Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and
Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice
Martin J. Edelman, Daniel P. Raymond, Dwight H. Owen, Michelle B. Leavy, Kari Chansky, Sriram Yennu, Felix G. Fernandez, Carolyn J. Presley, Tithi Biswas, Gwendolyn P. Quinn, Matthew B. Schabath, Seth Sheffler-Collins, Laura Chu, and Richard E. Gliklich
immunotherapy with chemotherapy, and which patients are unlikely to receive clinical benefit from immunotherapy. To address these and other research questions critical to improving patient outcomes, innovative research strategies and high-quality sources of data
The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis
George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles, and the Genitourinary Radiation Oncologists of Canada (GUROC)
pretreatment risk stratification systems have been published to support decision-making, interphysician communication, clinical trial stratification/design, and outcome reporting in nonmetastatic prostate cancer. Five unique commonly used systems (not
Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112
Tarah J. Ballinger, Helga S. Marques, Gloria Xue, Richard Hoffman, Constantine Gatsonis, Fengmin Zhao, Kathy D. Miller, Joseph Sparano, and Roisin M. Connolly
Background Observational data investigating the relationship between body habitus and outcomes in breast cancer have been largely centered in the curative setting and focused on weight-based metrics, with variable and inconsistent results
Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States
Christopher Nevala-Plagemann, Siddharth Iyengar, Andrew D. Trunk, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna
over the past several decades. This decrease is likely attributable to improved detection of early-stage disease through increased use of appropriate cancer screening and improvements in cytotoxic and targeted therapy. Unfortunately, outcomes for
Operative Techniques in Early-Stage Lung Cancer
Thomas A. D'Amico
patients. 12 , 13 Despite these outcomes, the advantages of thoracoscopic lobectomy seem to be underused. From 1999 to 2006, only 20% of all lobectomies for NSCLC were performed thoracoscopically by the board-certified thoracic surgeons participating in
Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy
P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault, and Areej El-Jawahri
, 5 , 11 However, data describing healthcare utilization and end-of-life (EoL) outcomes in this population are lacking. In the present study, we sought to describe the healthcare utilization and EoL outcomes among patients treated with CAR T
Role of Radioactive Iodine for Adjuvant Therapy and Treatment of Metastases
Jacqueline Jonklaas
between effective radiation dose and outcome of radioiodine therapy for thyroid cancer . N Engl J Med 1983 ; 309 : 937 – 941 . 16. Maxon HR III Englaro EE Thomas SR . Radioiodine-131 therapy for well-differentiated thyroid cancer
